These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20154000)

  • 1. [Prediction of the disease course in inflammatory bowel diseases].
    Kiss LS; Lakatos PL
    Orv Hetil; 2010 Feb; 151(8):293-301. PubMed ID: 20154000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic antiglycan antibodies in inflammatory bowel disease.
    Lakatos PL; Papp M; Rieder F
    Am J Gastroenterol; 2011 Mar; 106(3):406-12. PubMed ID: 21245832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for identifying Crohn's disease patients with poor prognosis.
    Miheller P; Kiss LS; Juhasz M; Mandel M; Lakatos PL
    Expert Rev Clin Immunol; 2013 Jan; 9(1):65-75; quiz 76. PubMed ID: 23256765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of disease course in inflammatory bowel diseases.
    Lakatos PL
    World J Gastroenterol; 2010 Jun; 16(21):2589-90. PubMed ID: 20518078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
    Vucelic B
    Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostics of inflammatory bowel disease.
    Nikolaus S; Schreiber S
    Gastroenterology; 2007 Nov; 133(5):1670-89. PubMed ID: 17983810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
    Henriksen M; Jahnsen J; Lygren I; Sauar J; Schulz T; Stray N; Vatn MH; Moum B;
    Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, serological and genetic predictors of inflammatory bowel disease course.
    Beaugerie L; Sokol H
    World J Gastroenterol; 2012 Aug; 18(29):3806-13. PubMed ID: 22876031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU).
    Mehdizadeh S; Chen G; Enayati PJ; Cheng DW; Han NJ; Shaye OA; Ippoliti A; Vasiliauskas EA; Lo SK; Papadakis KA
    Endoscopy; 2008 Jan; 40(1):30-5. PubMed ID: 18058654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we predict the high-risk patient?
    Benitez JM; Louis E
    Dig Dis; 2014; 32(4):328-36. PubMed ID: 24969276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.
    Romberg-Camps MJ; Dagnelie PC; Kester AD; Hesselink-van de Kruijs MA; Cilissen M; Engels LG; Van Deursen C; Hameeteman WH; Wolters FL; Russel MG; Stockbrügger RW
    Am J Gastroenterol; 2009 Feb; 104(2):371-83. PubMed ID: 19174787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wireless capsule in inflammatory bowel disease.
    Flamant M; Trang C; Bourreille A
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S183-9. PubMed ID: 20117341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic scoring systems for inflammatory bowel disease: pros and cons.
    Tontini GE; Bisschops R; Neumann H
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):543-54. PubMed ID: 24650249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal markers of gastrointestinal inflammation.
    Sherwood RA
    J Clin Pathol; 2012 Nov; 65(11):981-5. PubMed ID: 22813730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.